期刊
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
卷 40, 期 7, 页码 1406-1414出版社
WILEY
DOI: 10.1002/hed.25114
关键词
American Joint Committee on Cancer (AJCC) eighth edition staging; cutaneous squamous cell carcinoma; immunosuppression; in-transit metastasis; postoperative radiotherapy
资金
- AstraZeneca
- Merck
- Bristol-Myers Squibb
- Oncosec
- Menlo Therapeutics
- Leo Pharma
- Genentech/Roche
- Anacor
- Allergan
- Genentech
Background: The purpose of this study was to assess changes resulting from the American Joint Committee on Cancer (AJCC) eighth edition for cutaneous squamous cell carcinoma (SCC) and evaluate pertinent excluded factors. Methods: In 101 patients receiving surgery and postoperative radiation, recurrence and survival were estimated by cumulative incidence and Kaplan-Meier method. Time-to-event analysis was performed using Cox proportional hazards and Fine-Gray competing risks regression models. Results: The 2-year locoregional recurrence, overall survival (OS), and causespecific mortality rates were 25%, 72%, and 13%, respectively. The AJCC eighth edition upstaged T classification in 50% of patients and overall stage in 39%. In multivariate analysis, immunosuppression and in-transit metastasis were associated with locoregional recurrence. Older age and in-transit metastasis were associated with worse OS. In univariate analysis (limited by number of events), cause-specific mortality was associated with positive margin, in-transit metastasis, and the seventh edition dichotomized T classification and overall stage. Conclusion: In-transit metastasis was significantly associated with locoregional recurrence, OS, and cause-specific mortality. Efforts should be made to define intransit metastasis in the staging system.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据